title: Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose.
authors.forename: M
authors.initials: M
authors.lastname: Remberger
authors.forename: J
authors.initials: J
authors.lastname: Mattsson
authors.forename: B-M
authors.initials: BM
authors.lastname: Svahn
authors.forename: O
authors.initials: O
authors.lastname: Ringdén
mesh_terms: D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D035781:Siblings; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000379:methods*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents; D006680:HLA Antigens; D014740:Vidarabine; C024352:fludarabine